Compare Stocks: TGTX, BIIB, ALNY, and ROIV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$219.20 +1.4%	$280.12	$197.81 ▼ $495.55	$29.33B	0.3	2.31 million shs	1.74 million shs
BIIB Biogen	$207.94 +0.8%	$202.33	$127.00 ▼ $219.72	$30.72B	0.17	1.37 million shs	840,506 shs
ROIV Roivant Sciences	$36.34 +3.5%	$33.13	$10.90 ▼ $37.00	$26.14B	1.12	4.86 million shs	6.74 million shs
TGTX TG Therapeutics	$49.76 +0.4%	$51.47	$25.28 ▼ $59.30	$7.62B	1.62	2.32 million shs	1.77 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+6.66%	-29.92%	-25.71%	-48.80%
BIIB Biogen	0.00%	+2.46%	+4.54%	+7.49%	+60.77%
ROIV Roivant Sciences	0.00%	+7.17%	-1.28%	+27.24%	+211.80%
TGTX TG Therapeutics	0.00%	-4.36%	-15.75%	+16.10%	+79.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$219.20 +1.4%	$280.12	$197.81 ▼ $495.55	$29.33B	0.3	2.31 million shs	1.74 million shs
BIIB Biogen	$207.94 +0.8%	$202.33	$127.00 ▼ $219.72	$30.72B	0.17	1.37 million shs	840,506 shs
ROIV Roivant Sciences	$36.34 +3.5%	$33.13	$10.90 ▼ $37.00	$26.14B	1.12	4.86 million shs	6.74 million shs
TGTX TG Therapeutics	$49.76 +0.4%	$51.47	$25.28 ▼ $59.30	$7.62B	1.62	2.32 million shs	1.77 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+6.66%	-29.92%	-25.71%	-48.80%
BIIB Biogen	0.00%	+2.46%	+4.54%	+7.49%	+60.77%
ROIV Roivant Sciences	0.00%	+7.17%	-1.28%	+27.24%	+211.80%
TGTX TG Therapeutics	0.00%	-4.36%	-15.75%	+16.10%	+79.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.92	Moderate Buy	$396.72	80.98% Upside
BIIB Biogen	2.56	Moderate Buy	$224.61	8.02% Upside
ROIV Roivant Sciences	2.83	Moderate Buy	$34.77	-4.31% Downside
TGTX TG Therapeutics	2.44	Hold	$63.00	26.61% Upside

Current Analyst Ratings Breakdown

Latest TGTX, BIIB, ALNY, and ROIV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	ROIV Roivant Sciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $41.00
8/7/2026	ROIV Roivant Sciences	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$36.00 ➝ $42.00
8/7/2026	TGTX TG Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$65.00 ➝ $72.00
8/6/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/4/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$78.00
8/4/2026	ALNY Alnylam Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$410.00 ➝ $315.00
8/4/2026	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$221.00 ➝ $241.00
8/3/2026	BIIB Biogen	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$200.00 ➝ $215.00
8/3/2026	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$380.00 ➝ $340.00
8/3/2026	ALNY Alnylam Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Strong-Buy	$420.00
8/3/2026	ALNY Alnylam Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$527.00 ➝ $450.00

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	7.90	$2.80 per share	78.39	$10.12 per share	21.66
BIIB Biogen	$9.89B	3.11	$22.63 per share	9.19	$127.56 per share	1.63
ROIV Roivant Sciences	$8.26M	3,164.44	N/A	N/A	$6.84 per share	5.31
TGTX TG Therapeutics	$616.29M	12.36	$2.80 per share	17.76	$3.95 per share	12.60

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	40.74	22.72	N/A	15.26%	84.93%	14.30%	N/A
BIIB Biogen	$1.29B	$5.65	36.80	12.69	6.42	8.32%	11.18%	6.88%	N/A
ROIV Roivant Sciences	-$299.77M	-$0.60	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	N/A
TGTX TG Therapeutics	$447.18M	$2.74	18.16	17.90	1.65	55.22%	73.49%	34.14%	N/A

Latest TGTX, BIIB, ALNY, and ROIV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	3.06
BIIB Biogen	0.39	1.87	1.26
ROIV Roivant Sciences	N/A	13.80	18.37
TGTX TG Therapeutics	1.23	4.27	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
ROIV Roivant Sciences	64.76%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
ROIV Roivant Sciences	8.80%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
ROIV Roivant Sciences	860	719.27 million	655.97 million	Optionable
TGTX TG Therapeutics	290	153.07 million	139.49 million	Optionable

TGTX, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Brokerages

August 8 at 4:13 AM | marketbeat.com

JPMorgan Chase & Co. Issues Positive Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price

August 7 at 12:59 PM | marketbeat.com

Q4 EPS Estimates for TG Therapeutics Lifted by HC Wainwright

August 7 at 1:28 AM | americanbankingnews.com

California State Teachers Retirement System Increases Stock Position in TG Therapeutics, Inc. $TGTX

August 6 at 3:37 AM | marketbeat.com

Q3 EPS Estimates for TG Therapeutics Cut by HC Wainwright

August 6 at 1:13 AM | americanbankingnews.com

HC Wainwright Expects Higher Earnings for TG Therapeutics

August 5, 2026 | marketbeat.com

TG Therapeutics, Inc. $TGTX Shares Purchased by Sei Investments Co.

August 5, 2026 | marketbeat.com

Empowered Funds LLC Increases Stake in TG Therapeutics, Inc. $TGTX

August 5, 2026 | marketbeat.com

TG Therapeutics, Inc. $TGTX Stock Holdings Boosted by Dimensional Fund Advisors LP

August 5, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Stock Price Down 9% Following Weak Earnings

August 5, 2026 | americanbankingnews.com

TG Therapeutics Q3 EPS Estimate Lowered by HC Wainwright

August 4, 2026 | marketbeat.com

TG Therapeutics : TGTX

August 4, 2026 | 247wallst.com

TG Therapeutics (TGTX) Is Down 15.9% After Q2 Miss But Raised 2026 Outlook - What's Changed

August 4, 2026 | finance.yahoo.com

TG Therapeutics: Why I'm Staying Long After The Q2 Selloff

August 3, 2026 | seekingalpha.com

TG Therapeutics: Q2 Earnings Snapshot

August 3, 2026 | wtop.comW

TG Therapeutics (TGTX) Q2 2026 Earnings

August 3, 2026 | 247wallst.com

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

August 3, 2026 | uk.finance.yahoo.com

Three noteworthy biotechs just reported earnings — and only one recovered

August 3, 2026 | msn.com

TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss

August 3, 2026 | finance.yahoo.com

TG Therapeutics raises 2026 outlook following strong Briumvi sales growth

August 3, 2026 | msn.com

TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down

August 3, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TGTX, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$219.20 +3.08 (+1.43%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$218.44 -0.76 (-0.35%)

As of 08/7/2026 07:57 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$207.94 +1.66 (+0.80%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$207.60 -0.34 (-0.16%)

As of 08/7/2026 07:34 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Roivant Sciences NASDAQ:ROIV

$36.34 +1.22 (+3.47%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$35.08 -1.27 (-3.48%)

As of 08/7/2026 07:48 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

TG Therapeutics NASDAQ:TGTX

$49.76 +0.21 (+0.42%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$49.62 -0.14 (-0.27%)

As of 08/7/2026 07:58 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TGTX, BIIB, ALNY, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TGTX, BIIB, ALNY, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TGTX, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TGTX, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Roivant Sciences NASDAQ:ROIV

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TGTX, BIIB, ALNY, and ROIV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TGTX, BIIB, ALNY, and ROIV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TGTX, BIIB, ALNY, and ROIV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TGTX, BIIB, ALNY, and ROIV Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Roivant Sciences NASDAQ:ROIV

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools